We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The state’s supreme court affirmed that the sudden downturn in Akorn’s generic drug business — before the deal was final — justified Fresenius’ reversal. Read More
Garmin notes that the use of wearables as health and medical tools is rapidly evolving and the company is “committed to the development of wearables that can lead to the detection of serious health conditions.” Read More
CMS said the catalysts for slower retail drug spending include slower growth in the number of prescriptions dispensed and slower volume growth of expensive drugs. Read More
The company is developing he system for use in overactive bladder treatment, as well as deep brain stimulation for treating Parkinson’s disease. Read More
“Medicare isn’t proposing to set prices in Medicare Part B; it already sets prices in Medicare Part B,” said John O’Brien, senior advisor to the HHS Secretary for drug pricing reform. Read More
FDA Commissioner Scott Gottlieb noted an increase in new drugs targeting specific molecular markers that drive the growth and spread of cancer. Read More